Literature DB >> 26093340

Total, free, and complexed prostate-specific antigen levels among US men, 2007-2010.

David A Lacher1, Jeffery P Hughes2.   

Abstract

BACKGROUND: Screening for prostate cancer using prostate-specific antigen (PSA) is common. Prostate cancer has been associated with higher total PSA (tPSA), lower free PSA (fPSA), lower percent free PSA (%fPSA), and higher complexed PSA (cPSA).
METHODS: Total, free and complexed PSAs were performed on 3251 men ≥40years in the 2007-2010 National Health and Nutrition Examination Survey. Distributions of the PSA tests were examined by age, race and ethnicity, and body mass index (BMI) groups. Percentages of men at PSA thresholds were examined.
RESULTS: Total PSA geometric mean was 0.96μg/l among men aged ≥40years and increased from 0.74μg/l for men 40-49years, to 1.82μg/l for men 80years and older. Non-Hispanic Whites had lower age-adjusted mean tPSA (1.03μg/l) and cPSA (0.56μg/l) than non-Hispanic Blacks (tPSA 1.25μg/l and cPSA 0.72μg/l). Obese men had lower age-adjusted mean total, free and complexed PSAs (0.94, 0.27, and 0.51μg/l, respectively) than men with normal BMI (tPSA 1.21, fPSA 0.32, and cPSA 0.68μg/l, respectively).
CONCLUSION: Total, free and complexed PSAs increased with age; tPSA and cPSAs were highest in non-Hispanic Blacks; and total, free, and complexed PSAs were lowest in obese men. Published by Elsevier B.V.

Entities:  

Keywords:  National health survey; Prostate cancer; Prostate-specific antigen

Mesh:

Substances:

Year:  2015        PMID: 26093340      PMCID: PMC7456738          DOI: 10.1016/j.cca.2015.06.009

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  37 in total

1.  Age adjustment using the 2000 projected U.S. population.

Authors:  R J Klein; C A Schoenborn
Journal:  Healthy People 2010 Stat Notes       Date:  2001-01

2.  Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004.

Authors:  David M Werny; Trevor Thompson; Mona Saraiya; David Freedman; Benny J Kottiri; Robert R German; Mark Wener
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-12-19       Impact factor: 4.254

3.  Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark.

Authors:  Henrik Møller; Nina Roswall; Mieke Van Hemelrijck; Signe Benzon Larsen; Jack Cuzick; Lars Holmberg; Kim Overvad; Anne Tjønneland
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

4.  Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States.

Authors:  C Rodriguez; A V Patel; E E Calle; E J Jacobs; A Chao; M J Thun
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-04       Impact factor: 4.254

Review 5.  Molecular diagnosis of prostate cancer: are we up to age?

Authors:  Tapan Bhavsar; Peter McCue; Ruth Birbe
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

6.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

7.  Relationship between prostate-specific antigen, age, and body mass index in a prostate cancer screening population.

Authors:  Luke E Pater; Kimberly W Hart; Brian J Blonigen; Christopher J Lindsell; William L Barrett
Journal:  Am J Clin Oncol       Date:  2012-10       Impact factor: 2.339

8.  PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES.

Authors:  Jay H Fowke; Charles E Matthews
Journal:  Prostate       Date:  2010-02-01       Impact factor: 4.104

9.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.

Authors:  U H Stenman; J Leinonen; H Alfthan; S Rannikko; K Tuhkanen; O Alfthan
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

Review 10.  Biomarkers in prostate cancer: what's new?

Authors:  David A Sartori; Daniel W Chan
Journal:  Curr Opin Oncol       Date:  2014-05       Impact factor: 3.645

View more
  4 in total

1.  Simultaneous determination of free and total prostate-specific antigen by a magnetic particle-based time-resolved fluoroimmunoassay.

Authors:  Bin Zhou; Jue Zhang; Zhongwei Lv; Jun Fan; Yi Zhang; Biao Huang
Journal:  J Clin Lab Anal       Date:  2017-01-19       Impact factor: 2.352

2.  Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort.

Authors:  R Jeffrey Karnes; F Roy MacKintosh; Christopher H Morrell; Lori Rawson; Preston C Sprenkle; Michael W Kattan; Michele Colicchia; Thomas B Neville
Journal:  Front Oncol       Date:  2018-08-06       Impact factor: 6.244

3.  Establishment of reference intervals for serum [-2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men.

Authors:  Zhi-Yu Wu; Cheng Yang; Jie Luo; Shao-Li Deng; Bin Wu; Ming Chen
Journal:  Onco Targets Ther       Date:  2019-08-13       Impact factor: 4.147

4.  Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen.

Authors:  Sean Harrison; Kate Tilling; Emma L Turner; Richard M Martin; Rosie Lennon; J Athene Lane; Jenny L Donovan; Freddie C Hamdy; David E Neal; J L H Ruud Bosch; Hayley E Jones
Journal:  Cancer Causes Control       Date:  2020-03-11       Impact factor: 2.506

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.